Compare · NAUT vs RVTY
NAUT vs RVTY
Side-by-side comparison of Nautilus Biotechnology Inc. (NAUT) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAUT and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $17.26B, about 62.8x NAUT ($274.9M).
- Over the past year, NAUT is up 110.9% and RVTY is up 63.4% - NAUT leads by 47.5 points.
- RVTY has been more active in the news (7 items in the past 4 weeks vs 3 for NAUT).
- RVTY has more recent analyst coverage (23 ratings vs 9 for NAUT).
PerformanceNAUT+110.89%RVTY+63.42%
2025-10-17+0.00%2026-10-16
- Company
- Nautilus Biotechnology Inc.
- Revvity Inc.
- Price
- $2.06-4.19%
- $152.62-1.34%
- Market cap
- $274.9M
- $17.26B
- 1M return
- +112.15%
- +4.01%
- 1Y return
- +110.89%
- +63.42%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 3
- 7
- Recent ratings
- 9
- 23
NAUT
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Latest NAUT
- Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
- Roth Capital initiated coverage on Nautilus Biotechnology with a new price target
- SEC Form EFFECT filed by Nautilus Biotechnology Inc.
- SEC Form 424B5 filed by Nautilus Biotechnology Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-3 filed by Nautilus Biotechnology Inc.
- Leerink Partners initiated coverage on Nautilus Biotechnology with a new price target
- Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery